Premenstrual Dysphoric Disorder (PMDD)

The short version

●Premenstrual dysphoric disorder (PMDD) is a DSM-5-TR depressive disorder defined by severe mood symptoms (marked irritability, depressed mood, anxiety, affective lability) confined to the luteal phase of the menstrual cycle, with remission within a few days of menses onset and a symptom-free week post-menses.
●Diagnosis requires prospective daily symptom rating across at least two cycles — retrospective recall over-diagnoses. The luteal-phase timing and post-menstrual symptom-free interval are what distinguish PMDD from an underlying mood disorder that merely worsens premenstrually.
●First-line pharmacotherapy is SSRIs, which work differently here than in major depression: response is often rapid (days, not weeks) and luteal-phase-only (intermittent) dosing is effective for many patients, supporting a distinct serotonergic/neurosteroid mechanism.
●Drospirenone-containing combined oral contraceptives (e.g., drospirenone/ethinylestradiol 24/4) have FDA approval for PMDD and are first-line hormonal options, particularly when contraception is also desired.
●PMDD is distinct from premenstrual syndrome (PMS) — PMS is milder and lacks the marked affective symptoms and functional impairment that define PMDD. Roughly 3-8% of menstruating people meet PMDD criteria versus much higher rates of milder PMS.
●Ketamine is NOT a first-line or established PMDD treatment — the direct evidence base is thin and there is no PMDD-specific trial. It is reasonably considered only when a co-occurring treatment-resistant major depressive disorder (independent of cycle phase) is present alongside PMDD.

Clinical definition

DSM-5-TR classifies PMDD as a depressive disorder. Criteria require at least five symptoms in the final week before menses onset, improving within a few days of menses, and minimal or absent in the week post-menses, across most cycles in the preceding year. At least one symptom must be a core affective symptom: marked affective lability, marked irritability or anger or increased interpersonal conflict, markedly depressed mood or hopelessness, or marked anxiety or tension. Additional symptoms can include decreased interest, concentration difficulty, lethargy, appetite change, hypersomnia or insomnia, feeling overwhelmed, and physical symptoms (breast tenderness, bloating, joint or muscle pain). Symptoms must cause clinically significant distress or interference with work, school, or relationships, and must not be merely an exacerbation of another disorder. The diagnostic requirement that is most often skipped in practice is prospective daily symptom rating over at least two symptomatic cycles (e.g., the Daily Record of Severing Problems) — retrospective recall substantially over-attributes general mood symptoms to the cycle. ICD-11 codes PMDD under GA34.41 within diseases of the genitourinary system, cross-listed with mental disorders, reflecting its hybrid gynecologic-psychiatric nature. Current mechanistic understanding centers on abnormal sensitivity to normal cyclic fluctuations in the progesterone metabolite allopregnanolone (a GABA-A modulator) rather than abnormal hormone levels per se.

How it differs from related conditions

vs. Premenstrual syndrome (PMS)

PMS is milder, far more prevalent, and characterized predominantly by physical and mild mood symptoms without the marked affective symptoms (severe irritability, depression, lability) or functional impairment required for PMDD. PMDD is a formal DSM-5-TR diagnosis; PMS is not a psychiatric diagnosis. The threshold is symptom severity and impairment, confirmed by prospective rating.

vs. Premenstrual exacerbation of an underlying mood disorder

Many mood and anxiety disorders worsen premenstrually. The defining PMDD feature is the symptom-FREE interval in the follicular phase (week after menses). If symptoms are present — even if milder — throughout the cycle, the diagnosis is an underlying mood disorder with premenstrual exacerbation, not PMDD. This distinction changes treatment (continuous rather than luteal-only dosing).

vs. Major depressive disorder (MDD)

MDD symptoms persist regardless of cycle phase; PMDD symptoms remit in the follicular phase. The two can co-occur. Critically for ketamine consideration: it is the co-occurring cycle-independent MDD, if treatment-resistant, that might justify ketamine — not the PMDD itself.

vs. Perimenopausal mood symptoms

Perimenopause produces mood symptoms driven by erratic, declining estrogen rather than the cyclic luteal pattern of PMDD. Timing relative to a regular menstrual cycle and prospective charting distinguish them; treatment differs (perimenopausal symptoms may respond to estrogen stabilization).

First-line treatments

SSRIs — continuous dosing (sertraline, escitalopram, fluoxetine, paroxetine)

First-line and best-evidenced pharmacotherapy. The Cochrane review (Marjoribanks and colleagues) confirms SSRIs significantly reduce PMDD symptoms versus placebo. Continuous (everyday) dosing is the most studied schedule and appropriate for patients with longer symptomatic windows or co-occurring depression. Onset of benefit for PMDD is often within the first cycle — faster than the 4-8 week lag seen in major depression, reflecting a distinct mechanism.

SSRIs — luteal-phase (intermittent) dosing

A PMDD-specific strategy with strong evidence: the SSRI is taken only from ovulation (or symptom onset) until menses, then stopped. Effective for many patients, reduces total drug exposure and side-effect burden, and is well-supported in controlled trials (including luteal sertraline trials). The rapid response to intermittent dosing is itself evidence that PMDD is mechanistically distinct from major depression.

Drospirenone-containing combined oral contraceptives

Drospirenone/ethinylestradiol in a 24/4 regimen has FDA approval for PMDD. Drospirenone (an antimineralocorticoid, antiandrogenic progestin) appears better suited to PMDD than older progestins. First-line when contraception is also wanted; the shortened hormone-free interval reduces the hormonal fluctuation thought to trigger symptoms. Continuous or extended-cycle regimens (skipping the placebo week) can further reduce symptomatic intervals.

Calcium and lifestyle measures

Calcium supplementation (around 1,000-1,200 mg/day) has modest controlled-trial evidence for reducing premenstrual symptoms and is low-risk. Aerobic exercise, sleep regularization, and reduction of caffeine, alcohol, and sodium during the luteal phase are reasonable adjuncts. These are not sufficient as monotherapy for moderate-to-severe PMDD but improve overall symptom burden.

Cognitive-behavioral therapy (CBT)

CBT adapted for PMDD targets the cognitive and behavioral amplification of luteal-phase symptoms and improves coping and functional outcomes. Effect sizes are smaller than for SSRIs in acute symptom reduction but durability can be better, and CBT is a reasonable choice for patients who prefer to avoid medication or who have partial pharmacologic response.

GnRH agonists with add-back therapy (second-line/specialty)

For severe, refractory PMDD, gonadotropin-releasing hormone agonists (e.g., leuprolide) suppress ovarian cycling and abolish the hormonal trigger, with stable estrogen/progesterone add-back to prevent menopausal symptoms and bone loss. Highly effective but reserved for refractory cases under specialist care because of cost, side effects, and the need for add-back. A near-total response to GnRH agonist also serves as a diagnostic confirmation of PMDD.

SNRIs (venlafaxine) — alternative

Venlafaxine has controlled-trial support in PMDD and is a reasonable alternative when SSRIs are not tolerated or effective. Same rapid-onset pattern as SSRIs in PMDD. Standard SNRI considerations (blood pressure at higher doses, discontinuation effects) apply.

When standard treatments fail

PMDD that does not respond to an adequately dosed SSRI (continuous and/or luteal) should first prompt re-confirmation of the diagnosis with prospective daily charting — a substantial fraction of apparent SSRI-refractory PMDD is actually an underlying cycle-independent mood disorder requiring continuous treatment, or general PMS that does not meet PMDD criteria. The escalation pathway: try a second SSRI or switch SSRI-to-SNRI → trial a drospirenone-containing combined oral contraceptive (or continuous/extended-cycle regimen to eliminate the hormone-free interval) → add CBT → consider GnRH agonist with estrogen/progesterone add-back under specialist care (highly effective and diagnostically confirmatory) → in the most refractory, treatment-resistant cases, bilateral oophorectomy with hormone replacement is a definitive but irreversible last resort considered only in specialty settings. Co-occurring treatment-resistant major depression that persists across the whole cycle is evaluated and treated on its own track.

Where ketamine fits

Ketamine is NOT a first-line or established treatment for PMDD, and we will not represent it as one. There is no PMDD-specific clinical trial of ketamine, and the cyclic, hormonally-triggered mechanism of PMDD (sensitivity to luteal-phase allopregnanolone fluctuation acting on GABA-A receptors) is mechanistically distinct from the glutamatergic target of ketamine. The PMDD-specific treatments above — SSRIs in continuous or luteal dosing, drospirenone-containing oral contraceptives, and for refractory cases GnRH agonists — are the evidence-based pathway, and most patients with PMDD should be treated entirely within it. Ketamine enters the picture only in the specific scenario where a patient has a co-occurring, cycle-INDEPENDENT major depressive disorder that is itself treatment-resistant (failed two or more adequate antidepressant trials). In that situation, ketamine targets the treatment-resistant depression, not the PMDD; the luteal-phase PMDD symptoms still require their own dedicated treatment. Anyone whose mood symptoms remit fully in the follicular phase has PMDD, not treatment-resistant depression, and is not a ketamine candidate on that basis.

Where this fits with Tovani

Tovani does not treat PMDD as a standalone indication with ketamine — it is not an evidence-based use and we say so plainly. The appropriate first stop for PMDD is gynecologic and psychiatric care for SSRI (luteal or continuous) and/or drospirenone-based hormonal treatment. Where Tovani may be relevant is the patient who, alongside PMDD, also carries a separately diagnosed, cycle-independent treatment-resistant major depressive disorder. In that case eligibility screening evaluates the depression on its own merits (documented failure of two or more adequate antidepressant trials, with symptoms present throughout the cycle, not only luteally), and any ketamine treatment is directed at that depression while the PMDD is managed on its own track with first-line therapies, ideally in coordination with the patient's gynecologist or prescribing clinician.

Check eligibility The science behind ketamine

Frequently asked

How is PMDD different from really bad PMS?

PMDD is a formal DSM-5-TR psychiatric diagnosis requiring marked affective symptoms — severe irritability, depressed mood, anxiety, or mood lability — confined to the luteal phase, plus significant functional impairment, confirmed by prospective daily symptom charting over at least two cycles. PMS is milder, far more common, and lacks that level of mood disturbance and impairment. The severity, the predominance of affective symptoms, and the prospective confirmation are what separate them.

Why does my SSRI work within days for PMDD when it took weeks for depression?

This rapid response is a real and well-documented feature of PMDD and points to a different mechanism than major depression. In PMDD many patients respond within the first cycle, and luteal-phase-only (intermittent) dosing is effective — you take the medication only in the two weeks before your period. This fast, intermittent-dosing response is one of the clinical hallmarks distinguishing PMDD from major depressive disorder.

Can ketamine treat my PMDD?

No — ketamine is not an established or first-line treatment for PMDD, and we will not present it as one. There is no PMDD-specific trial, and the cyclic, hormone-triggered mechanism of PMDD is different from how ketamine works. The evidence-based path for PMDD is SSRIs (continuous or luteal-phase) and drospirenone-containing oral contraceptives, with GnRH agonists for refractory cases. Ketamine would only be relevant if you separately have a cycle-independent, treatment-resistant major depression in addition to PMDD — and even then it treats that depression, not the PMDD.

How do I know if it is PMDD or depression that gets worse before my period?

The key is the follicular phase — the week after your period. In true PMDD you are essentially symptom-free in that window. If you have meaningful mood symptoms throughout the cycle that simply intensify premenstrually, that is an underlying mood disorder with premenstrual exacerbation, which is treated continuously rather than only in the luteal phase. Prospective daily symptom rating across two cycles is how clinicians make this distinction.

What if SSRIs and birth control do not work for my PMDD?

First, the diagnosis is re-confirmed with prospective charting, because a lot of apparently refractory PMDD turns out to be an underlying mood disorder or general PMS. Genuine refractory PMDD can respond to switching SSRIs, trying continuous or extended-cycle oral contraceptives that remove the hormone-free week, adding CBT, or — under specialist care — a GnRH agonist with hormonal add-back, which is highly effective and also confirms the diagnosis. These steps, not ketamine, are the established escalation pathway.

References

Carlini SV, Deligiannidis KM. 2020, Journal of Clinical Psychiatry — Evidence-based treatment review of premenstrual dysphoric disorder — establishes SSRIs (continuous and luteal-phase dosing) and drospirenone-containing oral contraceptives as first-line, with GnRH agonists for refractory cases. (PMID 32023366)
Marjoribanks J et al. 2013, Cochrane Database of Systematic Reviews — Cochrane systematic review of selective serotonin reuptake inhibitors for premenstrual syndrome and PMDD — confirms significant symptom reduction versus placebo and supports both continuous and intermittent (luteal) dosing schedules. (PMID 23744611)
Cipriani A et al. 2018, Lancet — Network meta-analysis of 21 antidepressants in adult depression — informs SSRI/SNRI selection for the co-occurring cycle-independent depression that may accompany PMDD. (PMID 29477251)
Murrough JW et al. 2013, American Journal of Psychiatry — Ketamine RCT in treatment-resistant depression — relevant only to a co-occurring, cycle-independent treatment-resistant major depressive disorder, not to PMDD itself, for which ketamine is not an established treatment. (PMID 23982301)

Last reviewed by Dr. Ben Soffer, DO on May 27, 2026. This page is educational and not a substitute for clinical evaluation. A physician determines whether ketamine therapy is appropriate for your specific situation.